Exact Mass: 441.3031484
Exact Mass Matches: 441.3031484
Found 271 metabolites which its exact mass value is equals to given mass value 441.3031484,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Perindopril erbumine
C23H43N3O5 (441.32025480000004)
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure[1][2][3][4].
Leukotriene E3
C23H39NO5S (441.25488040000005)
Leukotriene E3 is an eicosanoid derived from 8,11,14-Eicosatrienoic acid by the 5-Lipoxygenase-Leukotriene Pathway. The eicosanoids are a diverse family of molecules that have powerful effects on cell function. They are best known as intercellular messengers, having autocrine and paracrine effects following their secretion from the cells that synthesize them. The diversity of possible products that can be synthesized from eicosatrienoic acid is due, in part to the variety of enzymes that can act on it. Studies have placed many, but not all, of these enzymes at or inside the nucleus. In some cases, the nuclear import or export of eicosatrienoic acid-processing enzymes is highly regulated. Furthermore, nuclear receptors that are activated by specific eicosanoids are known to exist. Taken together, these findings indicate that the enzymatic conversion of eicosatrienoic acid to specific signaling molecules can occur in the nucleus, that it is regulated, and that the synthesized products may act within the nucleus. Leukotriene E3 is also a by-product of the metabolism of leukotriene C3. Although they are primarily known for their roles in asthma, pain, fever and vascular responses, present evidence indicates that eicosanoids exert relevant effects on immune/inflammatory, as well as structural, cells pertinent to fibrogenesis. (PMID: 7306127, 8142566, 16574479, 15896193)Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. Leukotriene E3 is an eicosanoid derived from 8,11,14-Eicosatrienoic acid by the 5-Lipoxygenase-Leukotriene Pathway. The eicosanoids are a diverse family of molecules that have powerful effects on cell function. They are best known as intercellular messengers, having autocrine and paracrine effects following their secretion from the cells that synthesize them. The diversity of possible products that can be synthesized from eicosatrienoic acid is due, in part to the variety of enzymes that can act on it. Studies have placed many, but not all, of these enzymes at or inside the nucleus. In some cases, the nuclear import or export of eicosatrienoic acid-processing enzymes is highly regulated. Furthermore, nuclear receptors that are activated by specific eicosanoids are known to exist. Taken together, these findings indicate that the enzymatic conversion of eicosatrienoic acid to specific signaling molecules can occur in the nucleus, that it is regulated, and that the synthesized products may act within the nucleus. Leukotriene E3 is also a by-product of the metabolism of leukotriene C3. Although they are primarily known for their roles in asthma, pain, fever and vascular responses, present evidence indicates that eicosanoids exert relevant effects on immune/inflammatory, as well as structural, cells pertinent to fibrogenesis. (PMID: 7306127, 8142566, 16574479, 15896193)
3-Hydroxy-11Z-octadecenoylcarnitine
3-Hydroxy-11Z-octadecenoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxy-11Z-octadecenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxy-11Z-octadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-hydroxy-11Z-octadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 3-hydroxy-11Z-octadecenoylcarnitine is elevated in the blood or plasma of individuals with chronic fatigue syndrome (PMID: 21205027), mitochondrial trifunctional protein deficiency (PMID: 19880769), and psoriasis (PMID: 33391503). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]
3-Hydroxy-9Z-octadecenoylcarnitine
3-Hydroxy-9Z-octadecenoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxy-9Z-octadecenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxy-9Z-octadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-hydroxy-9Z-octadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 3-hydroxy-9Z-octadecenoylcarnitine is elevated in the blood or plasma of individuals with chronic fatigue syndrome (PMID: 21205027), mitochondrial trifunctional protein deficiency (PMID: 19880769), and psoriasis (PMID: 33391503). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]
(9Z)-3-Hydroxyoctadecenoylcarnitine
(9Z)-3-Hydroxyoctadecenoylcarnitine is an acylcarnitine. More specifically, it is an (9Z)-hydroxyoctadec-9-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z)-3-Hydroxyoctadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9Z)-3-Hydroxyoctadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (9Z)-3-Hydroxyoctadecenoylcarnitine is elevated in the blood or plasma of individuals with chronic fatigue syndrome (PMID: 21205027), mitochondrial trifunctional protein deficiency (PMID: 19880769), and psoriasis (PMID: 33391503). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(12E)-9-Hydroxyoctadecenoylcarnitine
(12E)-9-Hydroxyoctadecenoylcarnitine is an acylcarnitine. More specifically, it is an (12E)-9-hydroxyoctadec-12-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (12E)-9-Hydroxyoctadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (12E)-9-Hydroxyoctadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (12E)-9-Hydroxyoctadecenoylcarnitine is elevated in the blood or plasma of individuals with chronic fatigue syndrome (PMID: 21205027), mitochondrial trifunctional protein deficiency (PMID: 19880769), and psoriasis (PMID: 33391503). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(12Z)-10-Hydroxyoctadecenoylcarnitine
(12Z)-10-Hydroxyoctadecenoylcarnitine is an acylcarnitine. More specifically, it is an (12Z)-10-hydroxyoctadec-12-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (12Z)-10-Hydroxyoctadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (12Z)-10-Hydroxyoctadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (12Z)-10-Hydroxyoctadecenoylcarnitine is elevated in the blood or plasma of individuals with chronic fatigue syndrome (PMID: 21205027), mitochondrial trifunctional protein deficiency (PMID: 19880769), and psoriasis (PMID: 33391503). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(9Z)-12-Hydroxyoctadec-9-enoylcarnitine
(9Z)-12-hydroxyoctadec-9-enoylcarnitine is an acylcarnitine. More specifically, it is an (9Z)-12-hydroxyoctadec-9-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z)-12-hydroxyoctadec-9-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9Z)-12-hydroxyoctadec-9-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (9Z)-12-hydroxyoctadec-9-enoylcarnitine is elevated in the blood or plasma of individuals with chronic fatigue syndrome (PMID: 21205027), mitochondrial trifunctional protein deficiency (PMID: 19880769), and psoriasis (PMID: 33391503). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Oxooctadecanoylcarnitine
3-oxooctadecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-oxooctadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-oxooctadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-oxooctadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Arachidonoyl Histidine
N-arachidonoyl histidine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Arachidonic acid amide of Histidine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Arachidonoyl Histidine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Arachidonoyl Histidine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Docosahexaenoyl Isoleucine
N-docosahexaenoyl isoleucine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Isoleucine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Isoleucine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Isoleucine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Docosahexaenoyl Leucine
N-docosahexaenoyl leucine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Leucine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Leucine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Leucine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Pentanoic acid, 5-(dipentylamino)-5-oxo-4-((3-quinolinylcarbonyl)amino)-, (R)-
C25H35N3O4 (441.26274300000006)
4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol
4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol can be found in a number of food items such as nutmeg, common persimmon, common salsify, and lemon thyme, which makes 4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol a potential biomarker for the consumption of these food products.
4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol
4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol can be found in a number of food items such as wild celery, common cabbage, watermelon, and chestnut, which makes 4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol a potential biomarker for the consumption of these food products.
R-1 Methanandamide phosphate
C23H40NO5P (441.2643960000001)
(20R*,22R*)-N-methyl-5,6,12,13-tetrahydro-3beta,23beta-dihydroxy-5alpha,13beta,17beta,25alpha-veratraman-7,12(14)-dien-6-one|puqienine E
(2RS,3SR,3RS,3aSR,6SR,6aSR,6bSR,7aRS,11aSR,11bRS)-1,2,3,3a,4,4,5,6,6,6a,6b,7,7,7a,8,11,11a,11b-octadecahydro-7a-methoxy-3,6,10,11b-tetramethylspiro[9H-benzo[a]fluorene-9,2(3H)-furo[3,2-b]pyridin]-3-ol|23-methoxycyclopamine
(S,S)-ciliatamide A|ciliatamide A|N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-yl)dec-9-enamide
Ala Pro Arg Val
C19H35N7O5 (441.26995400000004)
Ala Pro Val Arg
C19H35N7O5 (441.26995400000004)
Ala Arg Pro Val
C19H35N7O5 (441.26995400000004)
Ala Arg Val Pro
C19H35N7O5 (441.26995400000004)
Ala Val Pro Arg
C19H35N7O5 (441.26995400000004)
Ala Val Arg Pro
C19H35N7O5 (441.26995400000004)
Gly Ile Pro Arg
C19H35N7O5 (441.26995400000004)
Gly Ile Arg Pro
C19H35N7O5 (441.26995400000004)
Gly Leu Pro Arg
C19H35N7O5 (441.26995400000004)
Gly Leu Arg Pro
C19H35N7O5 (441.26995400000004)
Gly Pro Ile Arg
C19H35N7O5 (441.26995400000004)
Gly Pro Leu Arg
C19H35N7O5 (441.26995400000004)
Gly Pro Arg Ile
C19H35N7O5 (441.26995400000004)
Gly Pro Arg Leu
C19H35N7O5 (441.26995400000004)
Gly Arg Ile Pro
C19H35N7O5 (441.26995400000004)
Gly Arg Leu Pro
C19H35N7O5 (441.26995400000004)
Gly Arg Pro Ile
C19H35N7O5 (441.26995400000004)
Gly Arg Pro Leu
C19H35N7O5 (441.26995400000004)
Ile Gly Pro Arg
C19H35N7O5 (441.26995400000004)
Ile Gly Arg Pro
C19H35N7O5 (441.26995400000004)
Ile Asn Pro Val
C20H35N5O6 (441.25872100000004)
Ile Asn Val Pro
C20H35N5O6 (441.25872100000004)
Ile Pro Gly Arg
C19H35N7O5 (441.26995400000004)
Ile Pro Asn Val
C20H35N5O6 (441.25872100000004)
Ile Pro Arg Gly
C19H35N7O5 (441.26995400000004)
Ile Pro Val Asn
C20H35N5O6 (441.25872100000004)
Ile Arg Gly Pro
C19H35N7O5 (441.26995400000004)
Ile Arg Pro Gly
C19H35N7O5 (441.26995400000004)
Ile Val Asn Pro
C20H35N5O6 (441.25872100000004)
Ile Val Pro Asn
C20H35N5O6 (441.25872100000004)
Lys Pro Pro Thr
C20H35N5O6 (441.25872100000004)
Lys Pro Thr Pro
C20H35N5O6 (441.25872100000004)
Lys Pro Val Val
Lys Thr Pro Pro
C20H35N5O6 (441.25872100000004)
Lys Val Pro Val
Lys Val Val Pro
Leu Gly Pro Arg
C19H35N7O5 (441.26995400000004)
Leu Gly Arg Pro
C19H35N7O5 (441.26995400000004)
Leu Asn Pro Val
C20H35N5O6 (441.25872100000004)
Leu Asn Val Pro
C20H35N5O6 (441.25872100000004)
Leu Pro Gly Arg
C19H35N7O5 (441.26995400000004)
Leu Pro Asn Val
C20H35N5O6 (441.25872100000004)
Leu Pro Arg Gly
C19H35N7O5 (441.26995400000004)
Leu Pro Val Asn
C20H35N5O6 (441.25872100000004)
Leu Arg Gly Pro
C19H35N7O5 (441.26995400000004)
Leu Arg Pro Gly
C19H35N7O5 (441.26995400000004)
Leu Val Asn Pro
C20H35N5O6 (441.25872100000004)
Leu Val Pro Asn
C20H35N5O6 (441.25872100000004)
Asn Ile Pro Val
C20H35N5O6 (441.25872100000004)
Asn Ile Val Pro
C20H35N5O6 (441.25872100000004)
Asn Leu Pro Val
C20H35N5O6 (441.25872100000004)
Asn Leu Val Pro
C20H35N5O6 (441.25872100000004)
Asn Pro Ile Val
C20H35N5O6 (441.25872100000004)
Asn Pro Leu Val
C20H35N5O6 (441.25872100000004)
Asn Pro Val Ile
C20H35N5O6 (441.25872100000004)
Asn Pro Val Leu
C20H35N5O6 (441.25872100000004)
Asn Val Ile Pro
C20H35N5O6 (441.25872100000004)
Asn Val Leu Pro
C20H35N5O6 (441.25872100000004)
Asn Val Pro Ile
C20H35N5O6 (441.25872100000004)
Asn Val Pro Leu
C20H35N5O6 (441.25872100000004)
Pro Ala Arg Val
C19H35N7O5 (441.26995400000004)
Pro Ala Val Arg
C19H35N7O5 (441.26995400000004)
Pro Gly Ile Arg
C19H35N7O5 (441.26995400000004)
Pro Gly Leu Arg
C19H35N7O5 (441.26995400000004)
Pro Gly Arg Ile
C19H35N7O5 (441.26995400000004)
Pro Gly Arg Leu
C19H35N7O5 (441.26995400000004)
Pro Ile Gly Arg
C19H35N7O5 (441.26995400000004)
Pro Ile Asn Val
C20H35N5O6 (441.25872100000004)
Pro Ile Arg Gly
C19H35N7O5 (441.26995400000004)
Pro Ile Val Asn
C20H35N5O6 (441.25872100000004)
Pro Lys Pro Thr
C20H35N5O6 (441.25872100000004)
Pro Lys Thr Pro
C20H35N5O6 (441.25872100000004)
Pro Lys Val Val
Pro Leu Gly Arg
C19H35N7O5 (441.26995400000004)
Pro Leu Asn Val
C20H35N5O6 (441.25872100000004)
Pro Leu Arg Gly
C19H35N7O5 (441.26995400000004)
Pro Leu Val Asn
C20H35N5O6 (441.25872100000004)
Pro Asn Ile Val
C20H35N5O6 (441.25872100000004)
Pro Asn Leu Val
C20H35N5O6 (441.25872100000004)
Pro Asn Val Ile
C20H35N5O6 (441.25872100000004)
Pro Asn Val Leu
C20H35N5O6 (441.25872100000004)
Pro Pro Lys Thr
C20H35N5O6 (441.25872100000004)
Pro Pro Thr Lys
C20H35N5O6 (441.25872100000004)
Pro Gln Val Val
C20H35N5O6 (441.25872100000004)
Pro Arg Ala Val
C19H35N7O5 (441.26995400000004)
Pro Arg Gly Ile
C19H35N7O5 (441.26995400000004)
Pro Arg Gly Leu
C19H35N7O5 (441.26995400000004)
Pro Arg Ile Gly
C19H35N7O5 (441.26995400000004)
Pro Arg Leu Gly
C19H35N7O5 (441.26995400000004)
Pro Arg Val Ala
C19H35N7O5 (441.26995400000004)
Pro Thr Lys Pro
C20H35N5O6 (441.25872100000004)
Pro Thr Pro Lys
C20H35N5O6 (441.25872100000004)
Pro Val Ala Arg
C19H35N7O5 (441.26995400000004)
Pro Val Ile Asn
C20H35N5O6 (441.25872100000004)
Pro Val Lys Val
Pro Val Leu Asn
C20H35N5O6 (441.25872100000004)
Pro Val Asn Ile
C20H35N5O6 (441.25872100000004)
Pro Val Asn Leu
C20H35N5O6 (441.25872100000004)
Pro Val Gln Val
C20H35N5O6 (441.25872100000004)
Pro Val Arg Ala
C19H35N7O5 (441.26995400000004)
Pro Val Val Lys
Pro Val Val Gln
C20H35N5O6 (441.25872100000004)
Gln Pro Val Val
C20H35N5O6 (441.25872100000004)
Gln Val Pro Val
C20H35N5O6 (441.25872100000004)
Gln Val Val Pro
C20H35N5O6 (441.25872100000004)
Arg Ala Pro Val
C19H35N7O5 (441.26995400000004)
Arg Ala Val Pro
C19H35N7O5 (441.26995400000004)
Arg Gly Ile Pro
C19H35N7O5 (441.26995400000004)
Arg Gly Leu Pro
C19H35N7O5 (441.26995400000004)
Arg Gly Pro Ile
C19H35N7O5 (441.26995400000004)
Arg Gly Pro Leu
C19H35N7O5 (441.26995400000004)
Arg Ile Gly Pro
C19H35N7O5 (441.26995400000004)
Arg Ile Pro Gly
C19H35N7O5 (441.26995400000004)
Arg Leu Gly Pro
C19H35N7O5 (441.26995400000004)
Arg Leu Pro Gly
C19H35N7O5 (441.26995400000004)
Arg Pro Ala Val
C19H35N7O5 (441.26995400000004)
Arg Pro Gly Ile
C19H35N7O5 (441.26995400000004)
Arg Pro Gly Leu
C19H35N7O5 (441.26995400000004)
Arg Pro Ile Gly
C19H35N7O5 (441.26995400000004)
Arg Pro Leu Gly
C19H35N7O5 (441.26995400000004)
Arg Pro Val Ala
C19H35N7O5 (441.26995400000004)
Arg Val Ala Pro
C19H35N7O5 (441.26995400000004)
Arg Val Pro Ala
C19H35N7O5 (441.26995400000004)
Thr Lys Pro Pro
C20H35N5O6 (441.25872100000004)
Thr Pro Lys Pro
C20H35N5O6 (441.25872100000004)
Thr Pro Pro Lys
C20H35N5O6 (441.25872100000004)
Val Ala Pro Arg
C19H35N7O5 (441.26995400000004)
Val Ala Arg Pro
C19H35N7O5 (441.26995400000004)
Val Ile Asn Pro
C20H35N5O6 (441.25872100000004)
Val Ile Pro Asn
C20H35N5O6 (441.25872100000004)
Val Lys Pro Val
Val Lys Val Pro
Val Leu Asn Pro
C20H35N5O6 (441.25872100000004)
Val Leu Pro Asn
C20H35N5O6 (441.25872100000004)
Val Asn Ile Pro
C20H35N5O6 (441.25872100000004)
Val Asn Leu Pro
C20H35N5O6 (441.25872100000004)
Val Asn Pro Ile
C20H35N5O6 (441.25872100000004)
Val Asn Pro Leu
C20H35N5O6 (441.25872100000004)
Val Pro Ala Arg
C19H35N7O5 (441.26995400000004)
Val Pro Ile Asn
C20H35N5O6 (441.25872100000004)
Val Pro Lys Val
Val Pro Leu Asn
C20H35N5O6 (441.25872100000004)
Val Pro Asn Ile
C20H35N5O6 (441.25872100000004)
Val Pro Asn Leu
C20H35N5O6 (441.25872100000004)
Val Pro Gln Val
C20H35N5O6 (441.25872100000004)
Val Pro Arg Ala
C19H35N7O5 (441.26995400000004)
Val Pro Val Lys
Val Pro Val Gln
C20H35N5O6 (441.25872100000004)
Val Gln Pro Val
C20H35N5O6 (441.25872100000004)
Val Gln Val Pro
C20H35N5O6 (441.25872100000004)
Val Arg Ala Pro
C19H35N7O5 (441.26995400000004)
Val Arg Pro Ala
C19H35N7O5 (441.26995400000004)
Val Val Lys Pro
Val Val Pro Lys
Val Val Pro Gln
C20H35N5O6 (441.25872100000004)
Val Val Gln Pro
C20H35N5O6 (441.25872100000004)
Leukotriene E3
C23H39NO5S (441.25488040000005)
A leukotriene that is leukotriene E4 in which the non-conjugated double bond has been reduced to a single bond.
cyclopropyl methyl amide
C27H39NO4 (441.28789340000003)
N-(α-Linolenoyl) Tyrosine
C27H39NO4 (441.28789340000003)
CAR 18:1;O
LPE O-15:0;O
C20H44NO7P (441.28552440000004)
[1,1-Bis(hydroxymethyl)-3-(4-octylphenyl)propyl]carbamic acid Phenylmethyl Ester
C27H39NO4 (441.28789340000003)
PHENOL, 2-(2H-BENZOTRIAZOL-2-YL)-6-(1-METHYL-1-PHENYLETHYL)-4-(1,1,3,3-TETRAMETHYLBUTYL)-
2-(dimethylamino)ethyl 2-methylprop-2-enoate,2-ethylhexyl prop-2-enoate,methyl 2-methylprop-2-enoate
C24H43NO6 (441.30902180000004)
3-Hydroxy-piperidine-1-carboxylic acid tert-butyl ester
Ciliatamide A
A lipopeptide that contains N-methylphenylalanine and lysine as the amino acid residues linked to a dec-9-enoyl moiety via an amide linkage (the R,R stereoisomer). It is isolated from the deep sea sponge Aaptos ciliata and exhibits antileishmanial activity.
5-Methyl-3-(9-oxo-1,8-diaza-tricyclo[10.6.1.013,18]nonadeca-12(19),13,15,17-tetraen-10-ylcarbamoyl)-hexanoic acid
C25H35N3O4 (441.26274300000006)
4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol
4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol can be found in a number of food items such as nutmeg, common persimmon, common salsify, and lemon thyme, which makes 4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol a potential biomarker for the consumption of these food products. 4α-carboxy-4β-methyl-5α-cholesta-8,24-dien-3β-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4α-carboxy-4β-methyl-5α-cholesta-8,24-dien-3β-ol can be found in a number of food items such as nutmeg, common persimmon, common salsify, and lemon thyme, which makes 4α-carboxy-4β-methyl-5α-cholesta-8,24-dien-3β-ol a potential biomarker for the consumption of these food products.
4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol
4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol can be found in a number of food items such as wild celery, common cabbage, watermelon, and chestnut, which makes 4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol a potential biomarker for the consumption of these food products. 4α-carboxy-ergosta-7,24(241)-dien-3β-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4α-carboxy-ergosta-7,24(241)-dien-3β-ol can be found in a number of food items such as wild celery, common cabbage, watermelon, and chestnut, which makes 4α-carboxy-ergosta-7,24(241)-dien-3β-ol a potential biomarker for the consumption of these food products.
(4S)-4-[(Z)-3-hydroxyoctadec-9-enoyl]oxy-4-(trimethylazaniumyl)butanoate
4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol
4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol can be found in a number of food items such as nutmeg, common persimmon, common salsify, and lemon thyme, which makes 4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol a potential biomarker for the consumption of these food products.
4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol
4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol can be found in a number of food items such as wild celery, common cabbage, watermelon, and chestnut, which makes 4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol a potential biomarker for the consumption of these food products.
4beta-Methylzymosterol-4alpha-carboxylate
A steroid acid anion that is the conjugate base of 4beta-methylzymosterol-4alpha-carboxylic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
4beta-Carboxy-4alpha-methyl-5alpha-cholesta-8,24-dien-3beta-ol
(E)-3,21-dihydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]henicos-5-enoate
2-[[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid
2-[[(4E,7E,10E,13E,16E,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-4-methylpentanoic acid
Lys-Thr-Pro-Pro
C20H35N5O6 (441.25872100000004)
A tetrapeptide composed of L-lysine, L-threonine and two L-proline units joined in sequence by peptide linkages.
3alpha,7alpha-Dihydroxy-5beta-cholane-24-sulfonate
C24H41O5S- (441.26745560000006)
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
(1R,9S,10S,11S)-5-(cyclopenten-1-yl)-10-(hydroxymethyl)-N,N-dimethyl-12-(oxan-4-ylmethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C25H35N3O4 (441.26274300000006)
(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C25H35N3O4 (441.26274300000006)
(2R,3R)-2-(hydroxymethyl)-1-(oxane-4-carbonyl)-N-propan-2-yl-3-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazaspiro[3.3]heptane-6-carboxamide
C25H35N3O4 (441.26274300000006)
(1S,9R,10R,11R)-5-(cyclopenten-1-yl)-10-(hydroxymethyl)-N,N-dimethyl-12-(oxan-4-ylmethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C25H35N3O4 (441.26274300000006)
(2S,3R)-2-(hydroxymethyl)-1-(oxane-4-carbonyl)-N-propan-2-yl-3-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazaspiro[3.3]heptane-6-carboxamide
C25H35N3O4 (441.26274300000006)
(2E)-19-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]nonadec-2-enoate
(4S)-4-[(Z)-3-hydroxyoctadec-11-enoyl]oxy-4-(trimethylazaniumyl)butanoate
(E,18R)-18-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxynonadec-2-enoate
(9Z)-3-hydroxyoctadecenoylcarnitine
An O-acylcarnitine having (9Z)-3-hydroxyoctadecenoyl as the acyl substituent.
O-(hydroxyoctadecenoyl)carnitine
An O-acylcarnitine having hydroxyoctadecenoyl as the acyl group in which the position of the double bond and hydroxy group are unspecified.
O-hydroxyoctadecenoyl-L-carnitine
An O-acyl-L-carnitine that is L-carnitine having a hydroxyoctadecenoyl group as the acyl substituent in which the position of the double bond and the hydroxy group is unspecified.
oscr#33(1-)
A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#33, obtained by deprotonation of the carboxy group; major species at pH 7.3.
CarE(18:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(3s,3ar,4s,6as,14r,15ar)-1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-14-(2-oxopropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione
C27H39NO4 (441.28789340000003)
(6e)-1-[(5s)-2,4-dihydroxy-5-[(s)-hydroxy(phenyl)methyl]-5h-pyrrol-3-yl]-4,6,8,10-tetramethyldodec-6-en-1-one
C27H39NO4 (441.28789340000003)
(3e,5e)-14-hydroxy-3,7,11-trimethyltetradeca-3,5-dien-1-yl 2-(hydroxymethyl)-1h-indole-3-carboxylate
C27H39NO4 (441.28789340000003)
(2s)-n-[(3s)-2-hydroxy-4,5,6,7-tetrahydro-3h-azepin-3-yl]-2-(n-methyldec-9-enamido)-3-phenylpropanimidic acid
1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-14-(2-oxopropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione
C27H39NO4 (441.28789340000003)
14-hydroxy-3,7,11-trimethyltetradeca-3,5-dien-1-yl 2-(hydroxymethyl)-1h-indole-3-carboxylate
C27H39NO4 (441.28789340000003)
(2r)-n-[(3r)-2-hydroxy-4,5,6,7-tetrahydro-3h-azepin-3-yl]-2-(n-methyldec-9-enamido)-3-phenylpropanimidic acid
1-{2,4-dihydroxy-5-[hydroxy(phenyl)methyl]-5h-pyrrol-3-yl}-4,6,8,10-tetramethyldodec-6-en-1-one
C27H39NO4 (441.28789340000003)